Management of ulcerative colitis: a clinical update

Burisch, 2013, Inflammatory bowel disease epidemiology, Curr Opin Gastroenterol, 29, 357, 10.1097/MOG.0b013e32836229fb Molodecky, 2012, Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review, Gastroenterology, 142, 46, 10.1053/j.gastro.2011.10.001 Kappelman, 2007, The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States, Clin Gastroenterol Hepatol, 5, 1424, 10.1016/j.cgh.2007.07.012 Solberg, 2009, Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study), Scand J Gastroenterol, 44, 431, 10.1080/00365520802600961 Büsch, 2014, Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study, Aliment Pharmacol Ther, 39, 57, 10.1111/apt.12528 Manninen, 2010, The epidemiology of inflammatory bowel diseases in Finland, Scand J Gastroenterol, 45, 1063, 10.3109/00365521.2010.485323 Jussila, 2013, High and increasing prevalence of inflammatory bowel disease in Finland with a clear North-South difference, J Crohn's Colitis, 7, e256, 10.1016/j.crohns.2012.10.007 Victoria, 2009, Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo state, Brazil, Arq Gastroenterol, 46, 20, 10.1590/S0004-28032009000100009 Truelove, 1955, Cortisone in ulcerative colitis: final report on a therapeutic trial, BMJ, 2, 1041, 10.1136/bmj.2.4947.1041 Schroeder, 1987, Coated oral 5-amino- salicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study, N Engl J Med, 317, 1625, 10.1056/NEJM198712243172603 Dignass, 2012, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis, J Crohn's Colitis, 6, 965, 10.1016/j.crohns.2012.09.003 Van Assche, 2013, European Crohn's and Colitis Organisation. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations, J Crohn's Colitis, 7, 1, 10.1016/j.crohns.2012.09.005 Dignass, 2012, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management, J Crohn's Colitis, 6, 991, 10.1016/j.crohns.2012.09.002 Gisbert, 2009, Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse, Inflamm Bowel Dis, 15, 1190, 10.1002/ibd.20933 Nerich, 2006, Geographical variations of inflammatory bowel disease in France: a study based on national health insurance data, Inflamm Bowel Dis, 12, 218, 10.1097/01.MIB.0000206540.38834.8c Rönnblom, 2010, Ulcerative colitis in the county of Uppsala 1945–2007: incidence and clinical characteristics, J Crohn's Colitis, 4, 523, 10.1016/j.crohns.2010.03.003 Flores, 2013, Imunomoduladores, 51 Zaltman, 2013, Salicilatos, 29 Ford, 2011, Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis, Am J Gastroenterol, 106, 601, 10.1038/ajg.2011.67 Khan, 2013, Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose, Inflamm Bowel Dis, 19, 1123, 10.1097/MIB.0b013e318280b1b8 Hanauer, 2005, Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial, Am J Gastroenterol, 100, 2478, 10.1111/j.1572-0241.2005.00248.x Teixeira, 2013, Biológicos, 73 Francesconi, 2013, Corticosteróides, 42 Travis, 2008, European evidence-based consensus on the management of ulcerative colitis: current management, J Crohn's Colitis, 2, 24, 10.1016/j.crohns.2007.11.002 Timmer, 2012, Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, 12, 9 Kennedy, 2013, A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis, Aliment Pharmacol Ther, 38, 1255, 10.1111/apt.12511 Rutgeerts, 2005, Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, 353, 2462, 10.1056/NEJMoa050516 Jarnerot, 2005, Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study, Gastroenterology, 128, 1805, 10.1053/j.gastro.2005.03.003 Gustavsson, 2010, Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3-year follow-up of the Swedish-Danish controlled infliximab study, Aliment Pharmacol Ther, 32, 984, 10.1111/j.1365-2036.2010.04435.x Panaccione, 2014, Combination therapy with Infliximab and Azathioprine is superior to monotherapy with either agent in ulcerative colitis, Gastroenterology, 146, 392, 10.1053/j.gastro.2013.10.052 Reinisch, 2011, Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomized controlled trial, Gut, 60, 780, 10.1136/gut.2010.221127 Sandborn, 2012, Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 142, 257, 10.1053/j.gastro.2011.10.032 Lopez, 2015, Efficacy of tumor necrosis factor antagonists on remission, colectomy and hospitalizations in ulcerative colitis: meta-analysis of placebo-controlled trials, Dig Liver Dis, 47, 356, 10.1016/j.dld.2015.01.148 Laharie, 2012, Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial, Lancet, 380, 1909, 10.1016/S0140-6736(12)61084-8 Van Assche, 2003, Randomized double-blind comparison of a 4mg/kg versus 2mg/kg intravenous cyclosporine in severe ulcerative colitis, Gastroenterology, 125, 1025, 10.1016/S0016-5085(03)01214-9 Kohn, 2007, Infliximab in severe ulcerative colitis: a short-term results of different infusion regimens and long-term follow-up, Aliment Pharmacol Ther, 26, 747, 10.1111/j.1365-2036.2007.03415.x Jarnerot, 2005, Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study, Gastroenterology, 128, 1805, 10.1053/j.gastro.2005.03.003 Gan, 2003, A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management, Am J Gastroenterol, 98, 2363, 10.1111/j.1572-0241.2003.07696.x Sheth, 1998, Toxic megacolon, Lancet, 351, 509, 10.1016/S0140-6736(97)10475-5